CLASS ACTION UPDATE for LOTZ, ITRM and PHG: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders

NEW YORK, NY / ACCESSWIRE / September 3, 2021 / Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead plaintiff have until the deadlines listed to petition the court. Further details about the cases can be found at the links provided. There is no cost or obligation to you.

LOTZ Shareholders Click Here: https://www.zlk.com/pslra-1/carlotz-inc-loss-submission-form?prid=19341&wire=1
ITRM Shareholders Click Here: https://www.zlk.com/pslra-1/iterum-therapeutics-plc-loss-submission-form?prid=19341&wire=1
PHG Shareholders Click Here: https://www.zlk.com/pslra-1/koninklijke-philips-n-v-loss-submission-form?prid=19341&wire=1
 

* ADDITIONAL INFORMATION BELOW *

CarLotz, Inc. (NASDAQ:LOTZ)

LOTZ Lawsuit on behalf of: investors who purchased December 30, 2020 - May 25, 2021
Lead Plaintiff Deadline: September 7, 2021
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/carlotz-inc-loss-submission-form?prid=19341&wire=1

According to the filed complaint, during the class period, CarLotz, Inc. made materially false and/or misleading statements and/or failed to disclose that: (1) due to a surge in inventory during the second half of fiscal 2020, CarLotz was experiencing a "logjam" resulting in slower processing and higher days to sell; (2) as a result, the Company's gross profit per unit would be negatively impacted; (3) to minimize returns to the corporate vehicle sourcing partner responsible for more than 60% of CarLotz's inventory, the Company was offering aggressive pricing; (4) as a result, CarLotz's gross profit per unit forecast was likely inflated; (5) this Company's corporate vehicle sourcing partner would likely pause consignments to the Company due to market conditions, including increasing wholesale prices; and (6) as a result of the foregoing, Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

Iterum Therapeutics Plc (NASDAQ:ITRM)

ITRM Lawsuit on behalf of: investors who purchased November 30, 2020 - July 23, 2021
Lead Plaintiff Deadline: October 4, 2021
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/iterum-therapeutics-plc-loss-submission-form?prid=19341&wire=1

According to the filed complaint, during the class period, Iterum Therapeutics Plc made materially false and/or misleading statements and/or failed to disclose that: (i) the sulopenem New Drug Application ("NDA") lacked sufficient data to support approval for the treatment of adult women with urinary tract infections caused by designated susceptible microorganisms proven or strongly suspected to be nonsusceptible to a quinolone; (ii) accordingly, it was unlikely that the Food and Drug Administration would approve the sulopenem NDA in its current form; (iii) Defendants downplayed the severity of issues and deficiencies associated with the sulopenem NDA; and (iv) as a result, the Company's public statements were materially false and misleading at all relevant times.

Koninklijke Philips N.V. (NYSE:PHG)

PHG Lawsuit on behalf of: investors who purchased February 25, 2020 - June 11, 2021
Lead Plaintiff Deadline: October 15, 2021
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/koninklijke-philips-n-v-loss-submission-form?prid=19341&wire=1

According to the filed complaint, during the class period, Koninklijke Philips N.V. made materially false and/or misleading statements and/or failed to disclose that: (i) Philips had deficient product manufacturing controls or procedures; (ii) as a result, the Company's Bi-Level PAP and CPAP devices and mechanical ventilators were manufactured using hazardous materials; (iii) accordingly, the Company's sales revenues from the foregoing products were unsustainable; (iv) the foregoing also subjected the Company to a substantial risk of a product recall, in addition to potential legal and/or regulatory action; and (v) as a result, the Company's public statements were materially false and misleading at all relevant times.

You have until the lead plaintiff deadlines to request that the court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.

Levi & Korsinsky is a nationally recognized firm with offices in New York, California, Connecticut, and Washington D.C. The firm's attorneys have extensive expertise and experience representing investors in securities litigation and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:

Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
Eduard Korsinsky, Esq.
55 Broadway, 10th Floor
New York, NY 10006
jlevi@levikorsinsky.com
Tel: (212) 363-7500
Fax: (212) 363-7171
www.zlk.com

SOURCE: Levi & Korsinsky, LLP